Psyched Wellness increases its bought deal offering from CAD$3 million to CAD$5.5 million.
Psychedelics
How the psychedelic Ibogaine helped a retired Vancouver firefighter treat his depression
In an interview with City News, a retired firefighter and rescue member from Vancouver says that Iboga, a psychedelic rainforest shrub that grows across West Africa, saved his life.
Cannabis compliance firm Allay Consulting adds psilocybin offering
Allay Consulting, a Portland, OR-based firm specializing in cannabis regulatory compliance consulting, has announced a new division to deliver regulatory compliance services in the legal therapeutic psilocybin market in Oregon, as well as other jurisdictions that follow suit.
Beckley Foundation: The Major Psychedelics Non-Profit Across The Pond
The UK-based Beckley Foundation is a psychedelics non-profit founded over 20 years ago that is having an increasing impact on the Psychedelics Revolution.
Mind Cure Health Inc. Announces an Increase to Previously Announced Bought Deal Public Offering
Mind Cure has upsized its bought deal financing by DOUBLE to CAD$20 million.
Numinus Announces Listing of New Warrants
Numinus announces the listing of its latest series of warrants for public trading, under the symbol "NUMI.WS". Warrants have an exercise price of CAD$0.90 and are valid until December 29, 2022.
Albert Labs inks LOI to undergo reverse takeover of ME Resource in move to expand access to psychedelics
Albert Labs, a privately held psychedelic drug developer, signed a letter of intent (LOI) on January 5 to be acquired by ME Resource Corp (CSE:MEC) (OTC:MEEXF), the latter company announced.
Psyched Wellness Announces C$3M Bought Deal Private Placement Led by Canaccord Genuity
Psyched Wellness announces a CAD$3 million bought deal with units priced at CAD$0.31.
The first-ever psychedelics ETF will launch next week, backed by a Canadian fund manager
The first-ever psychedelics ETF will begin trading on the Canadian NEO exchange next Wednesday, giving investors exposure to publicly-traded companies focused on the development of therapeutic solutions that utilize psychedelics.
New clinical trial to explore DMT as treatment for substance use disorders
The Canadian R&D company Entheon Biomedical has set out to investigate the therapeutic use of the psychedelic dimethyltryptamine (DMT) in treating addiction disorders. Specifically, the company has commissioned a clinical trial investigating the safety and efficacy of using intravenous DMT.
MindMed Announces the Start of the First-Ever Clinical Trial Combining MDMA and LSD
MindMed begins the first Phase 1 clinical trial testing the safety and tolerance of MDMA and LSD in combination.
Top Penny Stocks To Watch For 2021 If You’re Following Mushroom Stocks
Whether you’ve traded for decades or just opened an account, the market attracts you for a reason.
Silo Pharma Inc. Discusses The Potential of Merging Traditional Therapeutics with Psychedelic Research On The Stock Day Podcast
Phoenix, Arizona--(Newsfile Corp. - January 20, 2021) - The Stock Day Podcast welcomed Silo Pharma Inc. (OTCQB: SILO) ("the Company"), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson's, and other rare neurological disorders. CEO of the Company, Eric Weisblum, joined Stock Day host Everett Jolly.
Unique magic mushroom microdosing study to begin in Australia
A novel Australian trial is set to investigate the popular yet still deeply unproven practice of microdosing psychedelics.
Low Tide For Psychedelic Stocks With Media, Investors Distracted
The U.S. election has become a major political circus. With investors distracted and the media focused elsewhere, psychedelic stocks are temporarily at low tide.